GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan comp...
Uloženo v:
| Vydáno v: | Journal of translational medicine Ročník 15; číslo 1; s. 219 - 5 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
27.10.2017
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1479-5876, 1479-5876 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation.
Conclusions
Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. |
|---|---|
| AbstractList | GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Conclusions Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. Keywords: Nuclear magnetic resonance spectroscopy, GlycA, Inflammation, Cardiovascular disease GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation.BACKGROUNDGlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation.Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits.CONCLUSIONSCollectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Conclusions Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. Abstract Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Conclusions Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits. Reduced glycan mobility is another reason why some proteins with N-acetyl glucosamine residues, such as fibrinogen and immunoglobulin G (IgG), do not produce observable glycan NMR signals [1]. Since both positive acute phase protein levels and glycan complexity increase during inflammation, GlycA is higher in patients with acute febrile illnesses as well as chronic inflammatory diseases [3, 10, 11]. [...]while guidelines recommend two serial measurements be taken at least 2 weeks apart when using hsCRP for CV risk assessment, only one measurement is necessary for evaluation of a patient’s CV risk using the GlycA test [11]. Clinical utility of the GlycA test and future perspectives Based on the evidence gathered to date, GlycA test results may have clinical utility similar or complementary to hsCRP, fibrinogen and other biomarkers of inflammation [1, 14-20]. [...]GlycA may be used for the following intended uses: (1) as an aid in the identification and stratification of individuals at risk for future CV disease, (2) as an independent marker of prognosis for recurrent CV events in patients with stable coronary disease or acute coronary syndrome (ACS), (3) as an aid in the assessment of disease activity and risk of CV disease in adult RA and psoriasis patients when used in conjunction with standard clinical assessment and (4) in the evaluation of risk of progression to T2D along when considering measures of insulin resistance [43]. [...]the Phase III CANTOS study results revealed that treatment with the IL-1? antibody, canakinumab, in combination with standard of care therapy, reduced CV risk in people with a prior heart attack and inflammatory atherosclerosis [47]. |
| ArticleNumber | 219 |
| Audience | Academic |
| Author | Shalaurova, Irina Connelly, Margery A. Mehta, Nehal N. Playford, Martin P. Otvos, James D. |
| Author_xml | – sequence: 1 givenname: Margery A. surname: Connelly fullname: Connelly, Margery A. organization: Laboratory Corporation of America Holdings (LabCorp) – sequence: 2 givenname: James D. surname: Otvos fullname: Otvos, James D. organization: Laboratory Corporation of America Holdings (LabCorp) – sequence: 3 givenname: Irina surname: Shalaurova fullname: Shalaurova, Irina organization: Laboratory Corporation of America Holdings (LabCorp) – sequence: 4 givenname: Martin P. surname: Playford fullname: Playford, Martin P. organization: National Heart, Lung, and Blood Institute, National Institutes of Health – sequence: 5 givenname: Nehal N. surname: Mehta fullname: Mehta, Nehal N. email: nehal.mehta@nih.gov organization: National Heart, Lung, and Blood Institute, National Institutes of Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29078787$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ul1rFDEUDVKx7eoP8EUGfOmDU5P5yMeLsBRtCwUR9DncZJI125mkJjML--_NdNu6W1TykJCcc-69J-cUHfngDUJvCT4nhNOPiVSCshITVpK6IiV9gU5Iw0TZckaP9s7H6DSlNcZV0zbiFTquBGY8rxP07bLf6uWHAgofNqYvlAsDxFsTi2CLtE2jGZwunLc9DAOMLvgCfFdoiJ0LG0h66iEWnUsGkimiS7ev0UsLfTJvHvYF-vHl8_eLq_Lm6-X1xfKm1BTXY8lFxVuhRKW4ZZwa2ipCoaY1x5iymjfCWmZU02AQVijA0GnCMAeLRYsVrhfoeqfbBVjLu-hy31sZwMn7ixBXEuLodG-kUgQ6qxuDgTSqYbw2nEDecWdraknW-rTTupvUYDpt_BihPxA9fPHup1yFjWxpy0VueoHOHgRi-DWZNMrBJW36HrwJU5JEtKwRmGCRoe-fQddhij5blVE0_6uo6-oPagV5gOx_yHX1LCqXLSEse1DNHpz_BZVXN39bDot1-f6A8G5_0KcJHwORAWQH0DGkFI19ghAs59DJXehkDp2cQyfn4dkzjnbjfVZyN67_L7PaMVOu4lcm7nnxT9JvY_roxw |
| CitedBy_id | crossref_primary_10_1097_MOL_0000000000000620 crossref_primary_10_1186_s12950_023_00358_7 crossref_primary_10_1016_j_biopsych_2023_12_015 crossref_primary_10_1016_j_clnesp_2025_08_004 crossref_primary_10_1093_eurjpc_zwaf254 crossref_primary_10_1016_j_jlr_2022_100193 crossref_primary_10_1097_MOL_0000000000000867 crossref_primary_10_1038_s41598_024_69874_7 crossref_primary_10_1007_s11306_021_01803_5 crossref_primary_10_1038_s41598_025_94687_7 crossref_primary_10_1093_ije_dyaf065 crossref_primary_10_1161_JAHA_118_008681 crossref_primary_10_3390_nu12030806 crossref_primary_10_1016_j_ebiom_2022_104292 crossref_primary_10_3390_jcm9082472 crossref_primary_10_1186_s12916_021_01939_0 crossref_primary_10_1016_j_jad_2023_05_033 crossref_primary_10_1016_j_bbi_2023_02_010 crossref_primary_10_1080_01635581_2021_1957947 crossref_primary_10_1186_s12916_021_01913_w crossref_primary_10_3389_fcell_2021_720096 crossref_primary_10_3390_nu14214499 crossref_primary_10_1016_j_bbagen_2019_07_001 crossref_primary_10_1093_cdn_nzaa179 crossref_primary_10_3389_fnut_2022_807810 crossref_primary_10_1002_art_41518 crossref_primary_10_1002_mnfr_202001175 crossref_primary_10_3390_ijms25010188 crossref_primary_10_1371_journal_pone_0284570 crossref_primary_10_1038_s41597_020_0547_y crossref_primary_10_1093_ajcn_nqab132 crossref_primary_10_3389_fnut_2023_1230480 crossref_primary_10_3390_ijms24032319 crossref_primary_10_1038_s41392_023_01439_y crossref_primary_10_1002_oby_22882 crossref_primary_10_1093_ije_dyaf111 crossref_primary_10_1038_s43856_024_00669_7 crossref_primary_10_1177_26350106221137896 crossref_primary_10_1016_j_orcp_2023_08_003 crossref_primary_10_1161_CIRCIMAGING_117_007394 crossref_primary_10_1007_s00394_024_03383_1 crossref_primary_10_1093_rheumatology_kead590 crossref_primary_10_1016_j_bpsgos_2025_100482 crossref_primary_10_3390_antiox10030414 crossref_primary_10_3390_nu14091792 crossref_primary_10_1016_j_orcp_2020_04_004 crossref_primary_10_1016_j_jacl_2019_10_011 crossref_primary_10_1016_j_jad_2023_10_042 crossref_primary_10_1038_s41598_018_36450_9 crossref_primary_10_1016_j_atherosclerosis_2021_09_013 crossref_primary_10_3390_nu14235165 crossref_primary_10_1016_j_bbi_2021_11_001 crossref_primary_10_1016_j_mad_2024_112002 crossref_primary_10_1161_HYPERTENSIONAHA_122_20137 crossref_primary_10_3389_fimmu_2020_01034 crossref_primary_10_1016_j_bbi_2022_05_011 crossref_primary_10_1016_j_psyneuen_2020_104914 crossref_primary_10_1186_s12944_020_01273_z crossref_primary_10_1038_s41467_024_47845_w crossref_primary_10_1016_j_ajpc_2020_100120 crossref_primary_10_1210_clinem_dgae204 crossref_primary_10_1371_journal_pone_0223692 crossref_primary_10_1186_s12933_022_01652_z crossref_primary_10_3390_metabo14070372 crossref_primary_10_1016_j_atherosclerosis_2019_01_011 crossref_primary_10_1016_j_jacl_2020_07_012 crossref_primary_10_3389_fcvm_2021_691564 crossref_primary_10_3390_ijms26020459 crossref_primary_10_1016_j_ebiom_2021_103611 crossref_primary_10_1038_s41598_021_96833_3 crossref_primary_10_1136_lupus_2019_000332 crossref_primary_10_1186_s12933_025_02636_5 crossref_primary_10_1093_cvr_cvae123 crossref_primary_10_3389_fimmu_2022_909760 crossref_primary_10_1007_s42978_022_00186_w crossref_primary_10_3390_nu14122548 crossref_primary_10_1001_jamadermatol_2024_4433 crossref_primary_10_1016_j_burns_2024_10_003 crossref_primary_10_1016_j_clnu_2020_02_034 crossref_primary_10_1016_j_jcjd_2024_01_010 crossref_primary_10_1111_ijlh_12907 crossref_primary_10_1016_j_amjcard_2024_03_041 crossref_primary_10_1002_mnfr_201900482 crossref_primary_10_1038_s41598_021_90644_2 crossref_primary_10_3390_antiox9010079 crossref_primary_10_1016_j_jhepr_2025_101450 crossref_primary_10_1016_j_bbih_2022_100550 crossref_primary_10_1177_00220345231203562 crossref_primary_10_3390_nu16172866 crossref_primary_10_1161_CIRCGEN_118_002234 crossref_primary_10_3389_fmolb_2021_751637 crossref_primary_10_1007_s11883_023_01148_5 crossref_primary_10_1186_s12933_025_02581_3 crossref_primary_10_1111_imm_13739 crossref_primary_10_1186_s12940_022_00851_1 crossref_primary_10_1038_s44161_025_00700_7 crossref_primary_10_3389_fpubh_2023_1248609 crossref_primary_10_1016_j_biopsych_2024_11_004 crossref_primary_10_1111_sms_14337 crossref_primary_10_1038_s41390_019_0307_x crossref_primary_10_1007_s11306_020_01695_x crossref_primary_10_1021_acs_jproteome_5c00134 crossref_primary_10_3390_biomedicines12122884 crossref_primary_10_1093_sleep_zsab014 crossref_primary_10_1371_journal_pone_0308301 crossref_primary_10_7554_eLife_75170 crossref_primary_10_3390_nu15143244 crossref_primary_10_1016_j_jaad_2020_10_094 crossref_primary_10_3389_fendo_2021_775677 crossref_primary_10_3390_antiox11122319 crossref_primary_10_3389_fimmu_2019_02565 crossref_primary_10_1007_s11357_024_01279_w crossref_primary_10_1002_jcsm_12684 crossref_primary_10_1093_ije_dyz023 crossref_primary_10_1136_bmjdrc_2020_001953 crossref_primary_10_7554_eLife_73951 crossref_primary_10_1016_j_bbi_2024_06_002 crossref_primary_10_1016_j_jad_2020_03_074 crossref_primary_10_1128_spectrum_00893_21 crossref_primary_10_4239_wjd_v12_i8_1164 crossref_primary_10_1097_QAD_0000000000003094 crossref_primary_10_1002_anie_202306154 crossref_primary_10_1016_j_numecd_2022_02_011 crossref_primary_10_1186_s12986_023_00754_z crossref_primary_10_62347_APEX4060 crossref_primary_10_1007_s11306_019_1576_4 crossref_primary_10_1038_s41581_023_00797_8 crossref_primary_10_1136_annrheumdis_2021_220168 crossref_primary_10_3390_jcm12020487 crossref_primary_10_1016_j_yjmcc_2019_05_010 crossref_primary_10_3390_metabo12050383 crossref_primary_10_1093_eurheartj_ehaf553 crossref_primary_10_1111_eci_14305 crossref_primary_10_1016_j_gtc_2023_05_006 crossref_primary_10_1111_acps_13310 crossref_primary_10_3390_ijms22126310 crossref_primary_10_3390_jcm9020321 crossref_primary_10_3389_fmed_2022_1025375 crossref_primary_10_1038_s41366_022_01080_9 crossref_primary_10_1039_D3FO03575A crossref_primary_10_3390_jcm9040970 crossref_primary_10_3390_nu12092711 crossref_primary_10_1113_EP092768 crossref_primary_10_1016_j_sleep_2020_12_001 crossref_primary_10_1098_rsos_211642 crossref_primary_10_1016_j_amjcard_2023_07_034 crossref_primary_10_1016_j_jchromb_2024_124099 crossref_primary_10_1080_10408398_2023_2198605 crossref_primary_10_1111_sms_14553 crossref_primary_10_1016_j_ajcnut_2025_04_026 crossref_primary_10_1016_j_orcp_2024_09_274 crossref_primary_10_3390_antiox12112009 crossref_primary_10_3390_metabo12050376 crossref_primary_10_1002_ange_202306154 crossref_primary_10_1016_j_jacl_2019_09_012 crossref_primary_10_1111_eci_13320 crossref_primary_10_1016_j_ajcnut_2024_04_004 crossref_primary_10_1111_liv_15945 crossref_primary_10_1038_s41598_025_85134_8 crossref_primary_10_1186_s12989_023_00537_7 crossref_primary_10_1097_WAD_0000000000000431 crossref_primary_10_1007_s11695_025_08147_2 crossref_primary_10_15420_usc_2024_25 crossref_primary_10_3390_ijms25115981 crossref_primary_10_1089_thy_2023_0070 crossref_primary_10_3233_ADR_230154 crossref_primary_10_1210_clinem_dgac212 crossref_primary_10_1038_s42003_024_06146_0 crossref_primary_10_3390_biom14050563 crossref_primary_10_1016_j_ajpc_2022_100371 crossref_primary_10_1038_s41467_024_52310_9 crossref_primary_10_3389_fmicb_2024_1342653 crossref_primary_10_1016_j_ajpc_2022_100373 crossref_primary_10_1161_ATVBAHA_122_318004 crossref_primary_10_1016_j_mtbio_2025_102113 |
| Cites_doi | 10.1093/rheumatology/kew440 10.1161/01.CIR.0000054612.26458.B2 10.1016/0014-5793(87)80168-0 10.1136/ard.2010.135871 10.1177/0961203315617842 10.1007/s10753-014-0107-8 10.1186/s12887-016-0688-5 10.2337/dc16-1569 10.1111/eci.12481 10.1093/rheumatology/kep252 10.1007/s11882-014-0497-6 10.1161/CIRCGENETICS.114.000216 10.1007/s00403-016-1712-1 10.1093/aje/kwg135 10.1016/S0735-1097(17)34458-3 10.1016/j.metabol.2016.12.015 10.1161/ATVBAHA.115.305635 10.1097/HJH.0b013e32835bcce1 10.1016/j.atherosclerosis.2012.07.017 10.1161/JAHA.116.003822 10.1016/j.jacl.2015.11.009 10.1186/s13075-015-0646-x 10.1373/clinchem.2014.232918 10.1371/journal.pmed.1001606 10.1371/journal.pone.0165615 10.1371/journal.pone.0060759 10.1002/art.24092 10.1016/j.cca.2016.06.012 10.1016/j.acvd.2010.03.007 10.1371/journal.pone.0139057 10.1161/JAHA.114.001221 10.1373/clinchem.2016.261636 10.1093/rheumatology/keu224 10.1177/000456329303000404 10.1101/018655 10.1373/clinchem.2016.255828 10.1016/j.clinbiochem.2015.05.001 10.1016/j.clinbiochem.2015.06.016 10.1016/j.cca.2015.11.001 10.1186/s13075-016-0982-5 10.1136/ard.2003.018101 10.1016/j.cels.2015.09.007 10.1056/NEJMoa1707914 10.3899/jrheum.150437 10.1161/CIRCRESAHA.116.309637 10.1056/NEJM199902113400607 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2017 COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 |
| Copyright_xml | – notice: The Author(s) 2017 – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12967-017-1321-6 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 5 |
| ExternalDocumentID | oai_doaj_org_article_bb1adfc4e0a14b4783e81a4780df36f1 PMC5658936 A511795020 29078787 10_1186_s12967_017_1321_6 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: National Heart, Lung, and Blood Institute grantid: HL-006193-4 (Intramural grant to NNM from the NHLBI). funderid: http://dx.doi.org/10.13039/100000050 – fundername: ; grantid: HL-006193-4 (Intramural grant to NNM from the NHLBI). |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AHSBF AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-892859b92b8f786e65b16a363800673849ff7eb440a9f9ba0adc1708af0950b03 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 194 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000414078300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1479-5876 |
| IngestDate | Mon Nov 10 04:23:20 EST 2025 Tue Nov 04 01:43:20 EST 2025 Sun Nov 09 13:49:45 EST 2025 Sat Oct 18 23:53:43 EDT 2025 Tue Nov 11 09:46:19 EST 2025 Tue Nov 04 17:19:43 EST 2025 Wed Feb 19 02:44:35 EST 2025 Sat Nov 29 06:00:31 EST 2025 Tue Nov 18 20:36:41 EST 2025 Sat Sep 06 07:28:37 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Nuclear magnetic resonance spectroscopy GlycA Cardiovascular disease Inflammation |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-892859b92b8f786e65b16a363800673849ff7eb440a9f9ba0adc1708af0950b03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/1961189332?pq-origsite=%requestingapplication% |
| PMID | 29078787 |
| PQID | 1961189332 |
| PQPubID | 43076 |
| PageCount | 5 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_bb1adfc4e0a14b4783e81a4780df36f1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5658936 proquest_miscellaneous_1957490109 proquest_journals_1961189332 gale_infotracmisc_A511795020 gale_infotracacademiconefile_A511795020 pubmed_primary_29078787 crossref_primary_10_1186_s12967_017_1321_6 crossref_citationtrail_10_1186_s12967_017_1321_6 springer_journals_10_1186_s12967_017_1321_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-27 |
| PublicationDateYYYYMMDD | 2017-10-27 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAbbrev | J Transl Med |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2017 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | SC Ritchie (1321_CR3) 2015; 1 W Koenig (1321_CR38) 2003; 158 EG Gruppen (1321_CR8) 2015; 45 MA Connelly (1321_CR13) 2016; 459 E Choy (1321_CR33) 2014; 53 C Meune (1321_CR29) 2010; 103 JA Avina-Zubieta (1321_CR27) 2008; 59 DH Solomon (1321_CR25) 2003; 107 C Turesson (1321_CR26) 2004; 63 JB Muhlestein (1321_CR41) 2017; 69 JD Otvos (1321_CR1) 2015; 61 AA Joshi (1321_CR24) 2016; 119 K Fischer (1321_CR46) 2014; 11 EG Gruppen (1321_CR9) 2016; 10 E Alemao (1321_CR35) 2017; 56 MJ Ormseth (1321_CR5) 2015; 17 AO Akinkuolie (1321_CR18) 2016; 5 E Myasoedova (1321_CR32) 2011; 70 C Gabay (1321_CR42) 1999; 340 GH Clark (1321_CR37) 1993; 30 L Durcan (1321_CR23) 2016; 43 K Mokkala (1321_CR45) 2017; 69 RP Dullaart (1321_CR6) 2015; 48 AO Akinkuolie (1321_CR19) 2015; 35 EG Gruppen (1321_CR16) 2015; 10 P Bogaty (1321_CR40) 2013; 8 K Dungan (1321_CR4) 2015; 38 CP Chung (1321_CR22) 2016; 25 P Soininen (1321_CR44) 2015; 8 MA Connelly (1321_CR11) 2016; 16 RW McGarrah (1321_CR14) 2017; 63 PM Ridker (1321_CR47) 2017; 377 PD Chandler (1321_CR36) 2016; 11 RP Dullaart (1321_CR7) 2015; 48 SC Ritchie (1321_CR10) 2015 AO Akinkuolie (1321_CR15) 2014; 3 MA Connelly (1321_CR43) 2015; 2 C Lorenzo (1321_CR12) 2017; 40 L Raaby (1321_CR31) 2017; 309 JD Bell (1321_CR2) 1987; 215 DB Bartlett (1321_CR21) 2016; 18 DA Duprez (1321_CR17) 2016; 62 AW Armstrong (1321_CR30) 2013; 31 EM DeGoma (1321_CR39) 2012; 224 C Meune (1321_CR28) 2009; 48 A Bag-Ozbek (1321_CR34) 2015; 15 MA Connelly (1321_CR20) 2016; 452 27811210 - Clin Chem. 2017 Jan;63(1):288-296 28087832 - Rheumatology (Oxford). 2017 May 1;56(5):777-786 27173011 - Clin Chem. 2016 Jul;62(7):1020-31 28845751 - N Engl J Med. 2017 Sep 21;377(12 ):1119-1131 28213804 - Arch Dermatol Res. 2017 Apr;309(3):225-228 26834214 - J Rheumatol. 2016 Apr;43(4):745-50 27136058 - Cell Syst. 2015 Oct 28;1(4):293-301 25779987 - Clin Chem. 2015 May;61(5):714-23 27596163 - BMC Pediatr. 2016 Sep 05;16(1):151 27312321 - Clin Chim Acta. 2016 Aug 1;459:177-186 24586121 - PLoS Med. 2014 Feb 25;11(2):e1001606 24907149 - Rheumatology (Oxford). 2014 Dec;53(12):2143-54 12628952 - Circulation. 2003 Mar 11;107(9):1303-7 22846611 - Atherosclerosis. 2012 Sep;224(1):274-9 26081900 - Eur J Clin Invest. 2015 Aug;45(8):850-9 25977069 - Clin Biochem. 2015 Aug;48(12):811-4 25908766 - Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1544-50 26129880 - Clin Biochem. 2015 Nov;48(16-17):1045-7 27413042 - J Am Heart Assoc. 2016 Jul 13;5(7):null 25691689 - Circ Cardiovasc Genet. 2015 Feb;8(1):192-206 26549655 - Clin Chim Acta. 2016 Jan 15;452:10-7 27206938 - J Clin Lipidol. 2016 May-Jun;10 (3):512-8 28285651 - Metabolism. 2017 Apr;69:43-50 19696061 - Rheumatology (Oxford). 2009 Oct;48(10):1309-13 27902713 - PLoS One. 2016 Nov 30;11(11):e0165615 12915501 - Am J Epidemiol. 2003 Aug 15;158(4):357-64 23579782 - PLoS One. 2013 Apr 08;8(4):e60759 25586483 - Inflammation. 2015;38(3):1357-63 15051620 - Ann Rheum Dis. 2004 Aug;63(8):952-5 7691039 - Ann Clin Biochem. 1993 Jul;30 ( Pt 4):373-6 20656636 - Arch Cardiovasc Dis. 2010 Apr;103(4):253-61 27067270 - Arthritis Res Ther. 2016 Apr 12;18:86 27654120 - Circ Res. 2016 Nov 11;119(11):1242-1253 25956924 - Arthritis Res Ther. 2015 May 09;17:117 23249828 - J Hypertens. 2013 Mar;31(3):433-42; discussion 442-3 26398105 - PLoS One. 2015 Sep 23;10(9):e0139057 26637290 - Lupus. 2016 Mar;25(3):296-300 19035419 - Arthritis Rheum. 2008 Dec 15;59(12):1690-7 25504261 - Curr Allergy Asthma Rep. 2015 Feb;15(2):497 28031420 - Diabetes Care. 2017 Mar;40(3):375-382 21216812 - Ann Rheum Dis. 2011 Mar;70(3):482-7 25249300 - J Am Heart Assoc. 2014 Sep 23;3(5):e001221 2438159 - FEBS Lett. 1987 May 11;215(2):311-5 9971870 - N Engl J Med. 1999 Feb 11;340(6):448-54 |
| References_xml | – volume: 56 start-page: 777 issue: 5 year: 2017 ident: 1321_CR35 publication-title: Rheumatol doi: 10.1093/rheumatology/kew440 – volume: 107 start-page: 1303 year: 2003 ident: 1321_CR25 publication-title: Circulation doi: 10.1161/01.CIR.0000054612.26458.B2 – volume: 215 start-page: 311 year: 1987 ident: 1321_CR2 publication-title: FEBS Lett doi: 10.1016/0014-5793(87)80168-0 – volume: 70 start-page: 482 year: 2011 ident: 1321_CR32 publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.135871 – volume: 25 start-page: 296 year: 2016 ident: 1321_CR22 publication-title: Lupus doi: 10.1177/0961203315617842 – volume: 38 start-page: 1357 year: 2015 ident: 1321_CR4 publication-title: Inflammation doi: 10.1007/s10753-014-0107-8 – volume: 16 start-page: 151 year: 2016 ident: 1321_CR11 publication-title: BMC Pediatr doi: 10.1186/s12887-016-0688-5 – volume: 40 start-page: 375 issue: 3 year: 2017 ident: 1321_CR12 publication-title: Diabetes Care doi: 10.2337/dc16-1569 – volume: 45 start-page: 850 year: 2015 ident: 1321_CR8 publication-title: Eur J Clin Invest doi: 10.1111/eci.12481 – volume: 48 start-page: 1309 year: 2009 ident: 1321_CR28 publication-title: Rheumatol doi: 10.1093/rheumatology/kep252 – volume: 15 start-page: 497 year: 2015 ident: 1321_CR34 publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-014-0497-6 – volume: 8 start-page: 192 year: 2015 ident: 1321_CR44 publication-title: Circ Cardiovasc Genet doi: 10.1161/CIRCGENETICS.114.000216 – volume: 309 start-page: 225 year: 2017 ident: 1321_CR31 publication-title: Arch Dermatol Res doi: 10.1007/s00403-016-1712-1 – volume: 158 start-page: 357 year: 2003 ident: 1321_CR38 publication-title: Am J Epidemiol doi: 10.1093/aje/kwg135 – volume: 69 start-page: 1069 issue: 11 year: 2017 ident: 1321_CR41 publication-title: J Amer Coll Cardiol doi: 10.1016/S0735-1097(17)34458-3 – volume: 69 start-page: 43 year: 2017 ident: 1321_CR45 publication-title: Metabolism doi: 10.1016/j.metabol.2016.12.015 – volume: 35 start-page: 1544 year: 2015 ident: 1321_CR19 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.115.305635 – volume: 31 start-page: 433 year: 2013 ident: 1321_CR30 publication-title: J Hypertens doi: 10.1097/HJH.0b013e32835bcce1 – volume: 224 start-page: 274 year: 2012 ident: 1321_CR39 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2012.07.017 – volume: 5 start-page: e003822 issue: 7 year: 2016 ident: 1321_CR18 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.116.003822 – volume: 10 start-page: 512 year: 2016 ident: 1321_CR9 publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2015.11.009 – volume: 17 start-page: 117 year: 2015 ident: 1321_CR5 publication-title: Arthritis Res Ther doi: 10.1186/s13075-015-0646-x – volume: 61 start-page: 714 year: 2015 ident: 1321_CR1 publication-title: Clin Chem doi: 10.1373/clinchem.2014.232918 – volume: 11 start-page: e1001606 year: 2014 ident: 1321_CR46 publication-title: PLoS Med doi: 10.1371/journal.pmed.1001606 – volume: 11 start-page: e0165615 year: 2016 ident: 1321_CR36 publication-title: PLoS ONE doi: 10.1371/journal.pone.0165615 – volume: 8 start-page: e60759 year: 2013 ident: 1321_CR40 publication-title: PLoS ONE doi: 10.1371/journal.pone.0060759 – volume: 59 start-page: 1690 year: 2008 ident: 1321_CR27 publication-title: Arthritis Rheum doi: 10.1002/art.24092 – volume: 459 start-page: 177 year: 2016 ident: 1321_CR13 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2016.06.012 – volume: 103 start-page: 253 year: 2010 ident: 1321_CR29 publication-title: Arch Cardiovasc Dis doi: 10.1016/j.acvd.2010.03.007 – volume: 10 start-page: e0139057 year: 2015 ident: 1321_CR16 publication-title: PLoS ONE doi: 10.1371/journal.pone.0139057 – volume: 3 start-page: e001221 year: 2014 ident: 1321_CR15 publication-title: J Am Heart Assoc doi: 10.1161/JAHA.114.001221 – volume: 2 start-page: 000050 issue: 4 year: 2015 ident: 1321_CR43 publication-title: J Diab Metab Disord Contr – volume: 63 start-page: 288 year: 2017 ident: 1321_CR14 publication-title: Clin Chem doi: 10.1373/clinchem.2016.261636 – volume: 53 start-page: 2143 year: 2014 ident: 1321_CR33 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keu224 – volume: 30 start-page: 373 issue: Pt 4 year: 1993 ident: 1321_CR37 publication-title: Ann Clin Biochem doi: 10.1177/000456329303000404 – year: 2015 ident: 1321_CR10 publication-title: BioRxiv doi: 10.1101/018655 – volume: 62 start-page: 1020 year: 2016 ident: 1321_CR17 publication-title: Clin Chem doi: 10.1373/clinchem.2016.255828 – volume: 48 start-page: 811 year: 2015 ident: 1321_CR7 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2015.05.001 – volume: 48 start-page: 1045 year: 2015 ident: 1321_CR6 publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2015.06.016 – volume: 452 start-page: 10 year: 2016 ident: 1321_CR20 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2015.11.001 – volume: 18 start-page: 86 year: 2016 ident: 1321_CR21 publication-title: Arthritis Res Ther doi: 10.1186/s13075-016-0982-5 – volume: 63 start-page: 952 year: 2004 ident: 1321_CR26 publication-title: Ann Rheum Dis doi: 10.1136/ard.2003.018101 – volume: 1 start-page: 293 year: 2015 ident: 1321_CR3 publication-title: Cell Syst doi: 10.1016/j.cels.2015.09.007 – volume: 377 start-page: 1119 year: 2017 ident: 1321_CR47 publication-title: N Engl J Med doi: 10.1056/NEJMoa1707914 – volume: 43 start-page: 745 year: 2016 ident: 1321_CR23 publication-title: J Rheumatol doi: 10.3899/jrheum.150437 – volume: 119 start-page: 1242 year: 2016 ident: 1321_CR24 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.116.309637 – volume: 340 start-page: 448 year: 1999 ident: 1321_CR42 publication-title: N Engl J Med doi: 10.1056/NEJM199902113400607 – reference: 27067270 - Arthritis Res Ther. 2016 Apr 12;18:86 – reference: 12628952 - Circulation. 2003 Mar 11;107(9):1303-7 – reference: 26549655 - Clin Chim Acta. 2016 Jan 15;452:10-7 – reference: 27654120 - Circ Res. 2016 Nov 11;119(11):1242-1253 – reference: 26637290 - Lupus. 2016 Mar;25(3):296-300 – reference: 24586121 - PLoS Med. 2014 Feb 25;11(2):e1001606 – reference: 25249300 - J Am Heart Assoc. 2014 Sep 23;3(5):e001221 – reference: 25779987 - Clin Chem. 2015 May;61(5):714-23 – reference: 27206938 - J Clin Lipidol. 2016 May-Jun;10 (3):512-8 – reference: 27902713 - PLoS One. 2016 Nov 30;11(11):e0165615 – reference: 23579782 - PLoS One. 2013 Apr 08;8(4):e60759 – reference: 9971870 - N Engl J Med. 1999 Feb 11;340(6):448-54 – reference: 28845751 - N Engl J Med. 2017 Sep 21;377(12 ):1119-1131 – reference: 19696061 - Rheumatology (Oxford). 2009 Oct;48(10):1309-13 – reference: 23249828 - J Hypertens. 2013 Mar;31(3):433-42; discussion 442-3 – reference: 7691039 - Ann Clin Biochem. 1993 Jul;30 ( Pt 4):373-6 – reference: 26081900 - Eur J Clin Invest. 2015 Aug;45(8):850-9 – reference: 26834214 - J Rheumatol. 2016 Apr;43(4):745-50 – reference: 28031420 - Diabetes Care. 2017 Mar;40(3):375-382 – reference: 21216812 - Ann Rheum Dis. 2011 Mar;70(3):482-7 – reference: 26398105 - PLoS One. 2015 Sep 23;10(9):e0139057 – reference: 27136058 - Cell Syst. 2015 Oct 28;1(4):293-301 – reference: 25977069 - Clin Biochem. 2015 Aug;48(12):811-4 – reference: 22846611 - Atherosclerosis. 2012 Sep;224(1):274-9 – reference: 25504261 - Curr Allergy Asthma Rep. 2015 Feb;15(2):497 – reference: 19035419 - Arthritis Rheum. 2008 Dec 15;59(12):1690-7 – reference: 26129880 - Clin Biochem. 2015 Nov;48(16-17):1045-7 – reference: 25908766 - Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1544-50 – reference: 12915501 - Am J Epidemiol. 2003 Aug 15;158(4):357-64 – reference: 24907149 - Rheumatology (Oxford). 2014 Dec;53(12):2143-54 – reference: 25586483 - Inflammation. 2015;38(3):1357-63 – reference: 28213804 - Arch Dermatol Res. 2017 Apr;309(3):225-228 – reference: 28285651 - Metabolism. 2017 Apr;69:43-50 – reference: 27596163 - BMC Pediatr. 2016 Sep 05;16(1):151 – reference: 27312321 - Clin Chim Acta. 2016 Aug 1;459:177-186 – reference: 27173011 - Clin Chem. 2016 Jul;62(7):1020-31 – reference: 25956924 - Arthritis Res Ther. 2015 May 09;17:117 – reference: 27811210 - Clin Chem. 2017 Jan;63(1):288-296 – reference: 20656636 - Arch Cardiovasc Dis. 2010 Apr;103(4):253-61 – reference: 2438159 - FEBS Lett. 1987 May 11;215(2):311-5 – reference: 28087832 - Rheumatology (Oxford). 2017 May 1;56(5):777-786 – reference: 15051620 - Ann Rheum Dis. 2004 Aug;63(8):952-5 – reference: 25691689 - Circ Cardiovasc Genet. 2015 Feb;8(1):192-206 – reference: 27413042 - J Am Heart Assoc. 2016 Jul 13;5(7):null |
| SSID | ssj0024549 |
| Score | 2.591509 |
| SecondaryResourceType | review_article |
| Snippet | Background
GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use... GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients... Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use... Reduced glycan mobility is another reason why some proteins with N-acetyl glucosamine residues, such as fibrinogen and immunoglobulin G (IgG), do not produce... Abstract Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 219 |
| SubjectTerms | Acetylglucosamine - blood Biological markers Biomarkers - blood Biomedical and Life Sciences Biomedicine C-Reactive Protein - metabolism Cardiovascular Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - mortality GlycA Health aspects Health risk assessment Humans Identification and classification Inflammation Inflammation - blood Medicine/Public Health Metabolic and Lipoprotein Translation Mortality NMR Nuclear magnetic resonance Nuclear magnetic resonance spectroscopy Review Risk Factors |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEB7kEPFF_G31lAiCoJZL2zRNHlfx9MVDQeHeQpImuLB0ZXfvwP_emTRdtifqi-zDspu0m0xnMjObL98AvLAxCvQ7tqxlxASlEbpULX50da9s5RThKlOxie7sTJ2f688Hpb4IEzbSA4-CO3Gusn30InBbCSc61QRVWXznfWzw_rT6YtQzJVMTyx6mPXkPs1LyZIteTRLEsisx-6pKOfNCiaz_9yX5wCddxUte2TRNvuj0NtzKQSRbjIO_A9fCcBdufMrb5Pfgy4fVT794wywb1pdhxeiMPcFwNmwd2cjdvPQMdQvVYTy6yOzQMz_DprK8d8MIfX4fvp2-__ruY5lrJ5Re8mZXKk3MdE7XTsVOySBbV0nboLWl0jRK0H-1wQnBrY7aWW57X3Vc2YgxF3e8eQBHw3oIj4ApFwTGFTzwvhY9xwDG6uCt8OjbFWZ7BfBJlsZnYnGqb7EyKcFQ0oziNyh-Q-I3soBX-0t-jKwaf-v8lh7QviMRYqcvUE1MVhPzLzUp4CU9XkNmi4PzNp8-wCkSAZZZtMSN12LwXMDxrCeam583TwpisrlvDS5jOHbdNHUBz_fNdCVB2IawvqA-bScIDKMLeDjq035KtcZIDV8FdDNNm8153jIsvycycAzI8YdRSK8nnTwY1p9E-vh_iPQJ3KyTRfGy7o7haLe5CE_hur_cLbebZ8kefwH0LzYy priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEB_0FLkXvz2rp0QQBLWYtmmaPK7i6YuH39xbSNJUF5ZWdvcO_O-dSbPr9fwAZR-W3UzYZPqbzGRn8gvAQ9t1Av2OzUvZ4QalEjpXNX50Zats4RTVVcbLJprDQ3V0pN-mc9yrTbX7JiUZV-po1ko-W6FnklQm2eS4gypyeR4uoLdTZI3vP3z-SbCHO56Uvvxtt4kDijz9v67Gp9zR2VLJM_nS6IYOrvzXBK7C5RR1stkIk2twLvTX4dKblFe_Ae9eLb772VNmWT-chAWjQ_lUt7NkQ8dGsue5ZwhGxM941pHZvmV-UszKUrKHUbn6Tfh08PLji9d5umwh95JX61xporJzunSqa5QMsnaFtBWaZ7zLRgn6czc4IbjVnXaW29YXDVe2wyCNO17dgp1-6MNtYMoFgYEID7wtRcsx4rE6eCs8BgMKt4cZ8M0TMD4xkdOFGAsTdyRKmlFVBlVlSFVGZvB42-XbSMPxN-Hn9Fi3gsSgHb8Yll9MMkjjXGHbzovAbSGcaFQVVGHxnbddhbjN4BGBwpCd4-C8TccVcIrEmGVmNZHp1RhtZ7A_kUT79NPmDaxMWh9WBtc9HLuuqjKDB9tm6kk1b30YjkmmbgRVz-gM9kYUbqdUagzt8JVBM8HnZM7Tln7-NbKHYwSPP4xKerJB6alh_Umld_5J-i7slhHmPC-bfdhZL4_DPbjoT9bz1fJ-NNcfufE5EQ priority: 102 providerName: Springer Nature |
| Title | GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk |
| URI | https://link.springer.com/article/10.1186/s12967-017-1321-6 https://www.ncbi.nlm.nih.gov/pubmed/29078787 https://www.proquest.com/docview/1961189332 https://www.proquest.com/docview/1957490109 https://pubmed.ncbi.nlm.nih.gov/PMC5658936 https://doaj.org/article/bb1adfc4e0a14b4783e81a4780df36f1 |
| Volume | 15 |
| WOSCitedRecordID | wos000414078300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink customDbUrl: eissn: 1479-5876 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0024549 issn: 1479-5876 databaseCode: RSV dateStart: 20030601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFD5iLUK8cIcFRmUkJCQgqpO4ifOEOrQBD6vKuKg8WbbjsEpVMtpuEv-ecxK3W4bYE4rUKLWjxPHnc7GPvwPwUpelQL2jwzgt0UFJRB7KEV6auJA6MpLiKptkE9lkImezfOq3R698WOVGJjaCumV7prhtFMLDorY0Yz5E3KBljM54_O70V0g5pGit1SfU2IE-EW_JHvSnn46mPy6499AZ8iubkUyHK9R1KQVeZiH6ZFGYdnRTQ-H_t6C-pKmuRlFeWUptNNTh3f_btntwx1uqbNxC6z7ccNUDuHXk1-IfwucPi992_JZpVtXnbsFoIz_F-ixZXbKWIHpuGQIYMdfuj2S6KpjtBMAyv0DEKMT9EXw7PPj6_mPoEzSENuXJOpQ50d-ZPDayzGTq0pGJUp3gkG7y30hBE8LOCMF1XuZGc13YKONSl2jYccOTx9Cr6srtApPGCTReuONFLAqOVpLOndXCogEh0aUMgG-6RlnPXk5JNBaq8WJkqtreVNibinpTpQG83t5y2lJ3XFd5n_p7W5FYt5s_6uVP5QexMibSRWmF4zoSRmQycTLSeOZFmSDWA3hFaFEkG_DlrPZbHLCJxLKlxiMi4BuhhR7AXqcmjmnbLd4ARXmZslIXuAjgxbaY7qQ4ucrVZ1RnlAmKuMkDeNLCc9ukOEdzEI8Asg5wO23ullTzk4ZxHK1-fDB-pDcbiF96rX990qfXN-IZ3I6bocfDONuD3np55p7DTXu-nq-WA9jJZlnzKwfQ3z-YTI8HzXzJwA9qvDr-8v0PQQVV-w |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAwEv3C-BAUYCIQHRnMSNnQeEymVs2laBNKS-GdtxoFKVjLYb2p_iN3JOLt0yxN72gPJQpXba2PnOLf58DsAzUxQC7Y4J47TAACURWagGeGrjXJnIKuJV1sUm5GikxuPs8wr87vbCEK2y04m1os4rR-_I1xEp6Atj-B2_3f8ZUtUoWl3tSmg0sNj2R78wZJu_2fqAz_d5HG983Hu_GbZVBUKX8mQRqoxyttkstqqQKvXpwEapSRCHddEWJegtprdCcJMVmTXc5C6SXJkCvRFueYK_ewEuoh6XRCGT4-MAT2Cw1a6cRipdn6MtTYnYKUOM-aIw7dm-ukTA34bghCU8zdI8tVRbW8CN6__b3N2Aa62vzYaNcNyEFV_egsu7LZvgNnz5ND1yw9fMsLI69FNGqQiIrTRjVcGaFNcTx1AEUWqaHZ7MlDlzPQova5e4GJH078DXcxnQXVgtq9LfB6asF-h-cc_zWOQc_TyTeWeEQxdIYVAcAO8evnZt_nUqAzLVdRymUt3gRSNeNOFFpwG8XF6y3yQfOavzO0LUsiPlDa-_qGbfdauGtLWRyQsnPDeRsEKqxKvI4CfPiwSlNYAXhEdN2g1vzpl2kwYOkfKE6eGAUggOMMYIYK3XE7WS6zd3UNStVpzrYxwG8HTZTFcS06_01QH1GUhBnKEsgHuNACyHFGfo0OIRgOyJRm_M_ZZy8qPOmY5xC_4xTtKrTohO3Na_pvTB2YN4Alc293Z39M7WaPshXI1rQedhLNdgdTE78I_gkjtcTOazx7WaYPDtvGXrD7AanhY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3rb9MwED_BQBNfeD8CA4yEhAREcxInsT-WRwEB1RAP7ZtlO85WqUqmtpvEf89d4pRlPCSE-qFqfVbty53vrnf-HcBjU9cC7Y6J06LGACUTKpY5frRpJU1iJdVVds0mytlM7u-rvdDndDVUuw8pyf5OA6E0Nevdo6ruVVwWuyu0UgWVTJYxRlNJXJyHC4J6BlG4_vnbT7A9jH5CKvO300bGqMPs__VkPmWazpZNnsmddiZpeuW_N3MVLgdvlE168bkG53xzHbY_hnz7Dfj0ZvHdTZ4zw5r2xC8YXdanep4la2vWg0DPHUMhRbnq70Ay01TMjYpcWUgCMSpjvwlfp6-_vHwbhyYMsSt4to6lIog7q1Ir61IWvshtUpgM1bbrcSMF_enrrRDcqFpZw03lkpJLU6Pzxi3PbsFW0zb-DjBpvUAHhXtepaLi6AkZ5Z0RDp0EiWFjBHx4GtoFhHJqlLHQXaQiC92zSiOrNLFKFxE83Uw56uE5_kb8gh7xhpCQtbsv2uWBDoqqrU1MVTvhuUmEFaXMvEwMvvOqzlCeI3hCAqJJ_3FxzoRrDLhFQtLSk5xA9nL0wiPYGVGi3rrx8CBiOpwbK43nIa5dZVkawaPNMM2kWrjGt8dEk5eCqmpUBLd7idxsKVXo8uErgnIkq6M9j0ea-WGHKo6ePf4wMunZILGnlvUnlt79J-qHsL33aqo_vJu9vweX0k7ieZyWO7C1Xh77-3DRnaznq-WDTot_AFkfRNk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GlycA%2C+a+novel+biomarker+of+systemic+inflammation+and+cardiovascular+disease+risk&rft.jtitle=Journal+of+translational+medicine&rft.au=Connelly%2C+Margery+A&rft.au=Otvos%2C+James+D&rft.au=Shalaurova%2C+Irina&rft.au=Playford%2C+Martin+P&rft.date=2017-10-27&rft.pub=Springer+Nature+B.V&rft.eissn=1479-5876&rft.volume=15&rft_id=info:doi/10.1186%2Fs12967-017-1321-6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |